Compare Adaptive Biotechnologies Corp (ADPT) vs EHang Holdings Ltd - ADR (EH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs EHang Holdings Ltd - ADR — how do they compare? Adaptive Biotechnologies Corp trades at $20.24 (market cap $3.33B), while EHang Holdings Ltd - ADR trades at $5.63 (market cap $417.53M). The key difference: Adaptive Biotechnologies Corp is far larger — about 8× EHang Holdings Ltd - ADR's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, EHang Holdings Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| ADPT | EH | |
|---|---|---|
Market Cap | $3.33B | $417.53M |
Sector | Health | Industrials |
52-Week High | $22.37 | $19.99 |
52-Week Low | $10.24 | $5.52 |
Enterprise Value | $3.19B | $357.19M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
EHang Holdings trades at $5.52, down 12.52% over 24 hours, reflecting bearish technical signals and weak quarterly earnings. The company reported a net loss of $275.98 million for 2025 with a -77.56% net margin, though revenue reached $417.98 million. Recent news highlights volatility, including an 18% surge on June 15, 2026, following a Q1 2026 earnings miss reported by The Motley Fool on June 9, 2026.
The outlook remains challenged by persistent losses and high cash burn, but analyst consensus suggests moderate upside with a $7.75 price target. Key risks include execution delays in eVTOL commercialization and reliance on financing amid negative cash flows, while institutional sentiment is mixed with 40% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →
